Advances in DNA and mRNA-Based Strategies for Cancer Immunotherapy: Part A

by Elsevier Science, Neeraj Mishra PhD (Editor), Sumel Ashique PhD (Editor), Pranav Kumar Prabhakar PhD (Editor)

Overview

Advances in DNA and mRNA-Based Strategies for Cancer Immunotherapy, Volume 165 in the Advances in Immunology series, presents current developments and comprehensive reviews in DNA and mRNA vaccines: Significant therapeutic approach against cancer management, Nanoparticles for mRNA-based cancer immunotherapy, Nucleic acid Delivery as a therapeutic approach in cancer immunotherapy, Plasmid DNA and mRNA: Delivery approaches and challenges, Viral & Non-viral Delivery of mRNA against Cancer Cell, Progress in Modifying and Delivering mRNA therapies for Cancer Immunotherapy, and more.

Other chapters cover mRNA-Based Cancer Vaccines: A Novel Approach to Melanoma Treatment, Therapeutic mRNAs for cancer immunotherapy: from structure to delivery, Harnessing the immune system: Insights into cancer vaccines, Lipid Nanoparticle-Mediated mRNA Delivery in Cancer Immunotherapy, Immunotherapy Perspectives in the Era of B-Cell Editing in Cancer Treatment, Personalized Precision: Revolutionizing Cancer Treatment with mRNA-Based Vaccines in Melanoma Therapy, Revolutionizing Cancer Treatment: Exploring Novel Immunotherapeutics, Checkpoints, bispecifics, and Vaccines in Development, and more.

Product Details

ISBN-13:	9780443344954
Publisher:	Elsevier Science
Publication date:	05/29/2025
Series:	Advances in Immunology , #165
Pages:	198
Product dimensions:	6.00(w) x 9.00(h) x (d)

About the Author

Arun Kumar Singh earned his M. Pharm in Pharmaceutics from Galgotias University and currently serves as an Assistant Professor at the Amity Institute of Pharmacy, Amity University, Greater Noida. With over a decade of experience teaching pharmacology-related courses, Professor Singh has cultivated a diverse range of research interests, including nano-formulation, blockchain, IoT, machine learning, cancer, artificial intelligence, big data, and neuroscience. He has authored 5 book chapters, edited multiple books with notable international publishers, and has published 24 review papers, including two in the prestigious Biochimica et Biophysica Acta (BBA) – Reviews on Cancer. Renowned for his research acumen, innovative thinking, leadership, and positive outlook, Professor Singh's dedication and hard work have distinguished him as a leading figure in his field.

Dr. Neeraj Mishra is a Professor and Head of the Department of Pharmaceutics at Amity Institute of Pharmacy, India, a position he has held since July 2019. With nearly two decades of teaching and research experience, Dr. Mishra has authored over 100 publications on novel drug delivery systems, focusing on nanocarriers and microparticles for treating breast and colon cancer, as well as neurodegenerative disorders. He has written several books and book chapters, and holds three international and two Indian patents. Dr. Mishra has received numerous accolades, including the "Distinguished Professor Award" (2019, 2021) and the "Outstanding Scientist Award" (2020). He has served as a guest editor for Bentham Sciences and is recognized in Stanford University's World Scientists Rankings for 2022 and 2024.

Sumel Ashique has been working as an assistant professor at Bengal College of Pharmaceutical Sciences & Research, Durgapur 713212, West Bengal, India, West Bengal, India. He has 3.5 years of teaching experience. He has achieved 70+ publications of International and national accredited reputed journals (Scopus, UGC). He has knowledge in drug delivery, nanotechnology and targeted treatment strategy. He has also 6 granted patents from IP and Australia & 20 book chapters have been submitted to well-known publishers like Springer, Elsevier, Bentham and Taylor & Francis. Currently he is editing 13 books under CRC Press, Taylor & Francis, Springer and Wiley.

Dr. Pranav Kumar Prabhakar is currently working as a Professor in the Department of Biotechnology at Nagaland University, Kohima, Nagaland, India. He has been listed among the World’s Top 2% Scientists (as published by Stanford University, USA, in 2021, 2022, 2023, and 2024). He earned his PhD in Biotechnology from IIT Madras. His primary research interests include elucidating molecular mechanisms and strategies for oral insulin delivery and mimicking signaling pathways in metabolic disorders (diabetes) using natural products. He is a member of the Royal Society of Chemistry and the Asia-Pacific Chemical, Biological & Environmental Engineering Society. He also serves as an editorial board member and reviewer for several reputed national and international journals. Dr. Pranav has received various honors, including a travel grant to attend ATTD 2009 in Greece, sponsored by the Indian Institute of Technology Madras and the Council for Scientific and Industrial Research (CSIR), and approved by the Department of Science and Technology (DST). He has published over 115 research articles in journals, authored or edited 17 books, contributed more than 40 book chapters, and delivered 9 oral and poster presentations at scientific meetings.

Table of Contents

1. DNA and mRNA vaccines: Significant therapeutic approach against cancer management.
2. Nanoparticles for mRNA-based cancer immunotherapy
3. Nucleic acid Delivery as a therapeutic approach in cancer immunotherapy
4. Plasmid DNA and mRNA: Delivery approaches and challenges
5. Viral & Non-viral Delivery of mRNA against Cancer Cell
6. Progress in Modifying and Delivering mRNA therapies for Cancer Immunotherapy
7. mRNA-Based Cancer Vaccines: A Novel Approach to Melanoma Treatment
8. Therapeutic mRNAs for cancer immunotherapy: from structure to delivery
9. Harnessing the immune system: Insights into cancer vaccines
10. Lipid Nanoparticle-Mediated mRNA Delivery in Cancer Immunotherapy
11. Immunotherapy Perspectives in the Era of B-Cell Editing in Cancer Treatment
12. Personalized Precision: Revolutionizing Cancer Treatment with mRNA-Based Vaccines in Melanoma Therapy
13. Revolutionizing Cancer Treatment: Exploring Novel Immunotherapeutics, Checkpoints, bispecifics, and Vaccines in Development
14. Recent progress, challenges (stability and in vivo distribution), and opportunities of DNA and mRNA Vaccine in cancer Immunotherapy

What People are Saying About This

From the Publisher

Long-running serial that continually publishes cutting-edge reviews on the latest advancements in the field of immunology